8 Ways to Create Value in Cancer Care

Slideshow

This slide show features 8 ways oncologists can create value in cancer care, from building a great team of staff members to staying on top of the latest developments in your field.

References:

1. Krasner MS; Epstein RM, Beckman H, et al. Association of an educational program in mindful communication with burnout, empathy, and attitudes among primary care physicians. JAMA. 2009;302:1284-93.Read here.

Recent Videos
Yale’s COPPER Center aims to address disparities and out-of-pocket costs for patients, thereby improving the delivery of complex cancer treatment.
7 experts are featured in this series.
7 experts are featured in this series.
A study presented at ASTRO 2025 evaluated the feasibility of using a unified cancer database to consolidate information gathered across 14 institutions.
Non-Hodgkin lymphoma and other indolent forms of disease may require sequencing new treatments for years or decades, said Scott Huntington, MD, MPH, MSc.
Fixed-duration therapy may be more suitable for younger patients, while continuous therapy may benefit those who are older with more comorbidities.
Co-hosts Kristie L. Kahl and Andrew Svonavec highlight what to look forward to at the 2025 ESMO Annual Congress, from hot topics and emerging trends to travel recommendations.
Andrezj Jakubowiak, MD, PhD, prioritizes KRd-based regimens for the treatment of high-risk newly diagnosed disease in the post-transplant setting.
2 KOLs are featured in this series.
Related Content
The most pronounced overall and recurrence-free survival benefit with chemoradiotherapy was observed among patients with P53 abnormal endometrial cancer.

Adjuvant Chemotherapy Improves Long-Term Survival in Endometrial Cancer

Roman Fabbricatore
October 13th 2025
Article

The most pronounced overall and recurrence-free survival benefit with chemoradiotherapy was observed among patients with P53 abnormal endometrial cancer.

Jorge Cortes, MD, outlines the impact of imatinib in chronic myeloid leukemia and highlights future initiatives in the field.

Charting the Evolution of TKIs and Finding the Next Breakthrough in CML

Jorge E. Cortes, MD
October 13th 2025
Podcast

Jorge Cortes, MD, outlines the impact of imatinib in chronic myeloid leukemia and highlights future initiatives in the field.

Data from the FRUSICA-2 trial may support fruquintinib/sintilimab as a “valuable” option for patients with advanced renal cell carcinoma.

Fruquintinib Combo Prolongs PFS in Advanced/Metastatic RCC

Russ Conroy
October 13th 2025
Article

Data from the FRUSICA-2 trial may support fruquintinib/sintilimab as a “valuable” option for patients with advanced renal cell carcinoma.

A panel of oncology pharmacists discusses the role of lifileucel in metastatic melanoma and other considerations for using cellular therapy in solid tumors.

Optimizing Care for TILs, Cellular Therapy in Melanoma and Solid Tumors

Brooke Adams, PharmD, BCOP;Natalie Brumwell, PharmD, BCOP;Bryant A. Clemons, PharmD, BCOP
October 6th 2025
Podcast

A panel of oncology pharmacists discusses the role of lifileucel in metastatic melanoma and other considerations for using cellular therapy in solid tumors.

Domvanalimab is an Fc-silent anti-TIGIT antibody, and zimberelimab is an anti–PD-1 monoclonal antibody.

Anti-TIGIT Combination Therapy Yields Positive Survival in Gastric Cancers

Tim Cortese
October 13th 2025
Article

Survival results were similar among all patients and PD-L1 subgroups with the domvanalimab regimen in gastroesophageal junction adenocarcinoma.

Data from the AMPLITUDE trial may support widespread genomic testing at diagnosis to inform targeted therapy strategies for those with CSPC.

Niraparib Combo Boosts rPFS in Metastatic HRR-Altered CSPC

Russ Conroy
October 12th 2025
Article

Data from the AMPLITUDE trial may support widespread genomic testing at diagnosis to inform targeted therapy strategies for those with CSPC.